CD274 molecule
CD274 molecule (PD-L1) is a type I transmembrane glycoprotein that functions as an immune checkpoint ligand.
CD274 molecule (PD-L1) is a type I transmembrane glycoprotein that functions as an immune checkpoint ligand. It is expressed on the surface of antigen-presenting cells such as dendritic cells, on many tumor cells, and on stromal populations within the tumour microenvironment including cancer-associated fibroblasts. PD-L1 is also displayed on extracellular vesicles shed by both tumour and immune cells, a form in which it retains its inhibitory activity.
The protein exerts its effects by binding Programmed cell death 1 (PD-1) on activated T cells, delivering an inhibitory signal that dampens T cell proliferation, cytokine production, and cytotoxic T cell killing. This axis normally limits excessive immune activation and helps maintain peripheral tolerance, and regulatory T cells participate in the same restraint of effector responses. Tumours co-opt the pathway to escape immune surveillance, which makes PD-L1 both a marker of immune escape and a therapeutic target.
Blockade of the PD-1/PD-L1 axis is the basis of a major class of cancer immunotherapy. checkpoint inhibitor antibodies directed at PD-1 (pembrolizumab, nivolumab) or at PD-L1 itself (durvalumab) restore cytotoxic T cell activity against tumours, and PD-L1 expression measured by immunohistochemistry is used to help select patients in malignancies including lung cancer, head and neck squamous cell carcinoma, and others. The same axis contributes to T cell dysfunction in haematological settings such as multiple myeloma. Because these agents release a physiological brake on immunity, they carry characteristic immune-related adverse events, including inflammatory arthritis, myocarditis, myasthenia gravis, colitis, and endocrinopathies. PD-L1 is additionally being pursued beyond antibody blockade as a target for radioligand imaging and therapy and for targeted protein degradation strategies.
Where the papers sit
76 papers from the last 6 months study CD274 molecule directly · updated from PubMed 16 Nov 2026
Study type 6 clinical trials · 11 observational · 8 human data · 40 preclinical · 11 unclassified
Themes 7 themes · 1 paradigm shift
-
Breast Cancer Immune Evasion
Triple-negative breast cancer research is shifting toward combinations that activate CD8-positive T cells while correcting tumor, dendritic-cell and microbiome-mediated immune suppression. Vaccines, probiotics, chemoimmunotherapy and durvalumab-based regimens are paired with strategies targeting PD-L1, interferon signaling or metabolic resistance. The AR/ARD1/DLGAP5 axis, macrophage polarization and extracellular-vesicle PD-L1 recur as mechanisms of immune escape. Many delivery and protein-engineering platforms remain preclinical, leaving clinical durability and patient selection unresolved.
16 papers · 21.1%
-
Tumor Immune Evasion
Tumor immune evasion is being attacked through coordinated remodeling of cancer cells, stroma, macrophages and vasculature rather than checkpoint blockade alone. Recurrent targets include PD-L1 O-GlcNAcylation, mTOR signaling, glycolysis, CTGF-positive fibroblasts and tumor-associated macrophages. Local hydrogels, radionuclide therapy, engineered probiotics, mRNA nanoparticles and epigenetic inhibitors are used to convert immune-cold tumors into responsive ones. The central challenge is translating these multimodal combinations into durable systemic immunity without excessive complexity or toxicity.
13 papers · 17.1%
-
PD-1/PD-L1 Immunotherapy
PD-1/PD-L1 blockade is moving toward engineered combinations that reshape metabolism, angiogenesis and antigen presentation rather than relying on checkpoint inhibition alone. PRKX, miRNAs and NEK3-linked biology recur as regulators of PD-L1 or T-cell function, while nanocarriers and artificial antigen-presenting cells seek stronger systemic responses. Clinical benefit remains dependent on tumor context and PD-L1 expression. Myasthenia gravis and myocarditis underscore the need to balance immune activation with serious toxicity.
11 papers · 14.5%
-
PD-L1 Targeting Strategies
PD-L1 intervention is expanding beyond antibody blockade toward glycosylation control, small-molecule inhibitors, aptamers, protein degradation and radioligand-directed delivery. These approaches aim to remove or destabilize PD-L1 while combining checkpoint disruption with chemotherapy, oncolytic adenovirus or imaging. SRSF2-dependent splicing and PI3K/AKT signaling illustrate how tumor-intrinsic regulation can sustain immune evasion. Evidence spans multiple tumor types, so comparative efficacy, tissue selectivity and safety remain unsettled.
11 papers · 14.5%
-
Squamous Cancer Immunotherapy
Checkpoint therapy in squamous cancers is moving toward response selection by PD-L1 combined positive score, spatial expression and systemic immune state. Pembrolizumab is being tested with chemoradiotherapy or followed by salvage chemotherapy, while myeloid remodeling and cytokine profiles help explain response. Hypoxia, CDK4/6 signaling and GMPS-USP7 control of PD-L1 provide additional resistance mechanisms. Whether these biomarkers can reliably guide treatment across oral, cervical, esophageal and head and neck disease remains open.
9 papers · 11.8%
-
Colorectal Cancer Immunotherapy Resistance
Colorectal cancer strategies are moving toward reversing checkpoint resistance by targeting lactate, lactylation, desialylation and tumor-microenvironment barriers. Gemcitabine and NAT1-ENO1-lactate pathway inhibition are linked to PD-L1 destabilization, while CD28 siRNA delivery seeks to restore T-cell activity. Activatable antibody conjugates, extracellular-vesicle barriers and PD-L1 radiotracers add tumor-selective treatment and imaging. Anti-PD-1/PD-L1 combinations remain under clinical evaluation, but resistance mechanisms and benefit outside selected populations remain unresolved.
8 papers · 10.5%
-
PD-L1 Therapy in Lung Cancer
Non-small-cell lung cancer treatment is moving from pembrolizumab or nivolumab monotherapy toward perioperative, antibody-drug conjugate and radiation combinations. Sacituzumab tirumotecan plus pembrolizumab, neoadjuvant nivolumab with chemotherapy and adjuvant nivolumab address progression across disease stages. Imaging-based PD-L1 prediction and the PDK4/GLS metabolic axis seek better selection and reversal of anti-PD-1 resistance. PKC/XIAP signaling and PD-L1-targeted radiosensitizers provide additional routes to resensitize refractory tumors.
8 papers · 10.5%
PD-L1 on therapeutic antigen-presenting platforms is itself an immunosuppressive liability
The OVA-loaded bone-marrow-derived dendritic-cell extracellular-vesicle vaccine and the personalized STAR autologous tumor-derived microvesicle vaccine both found that PD-L1 associated with an immunotherapeutic vaccine platform undermines antitumor priming rather than merely serving as a checkpoint to target on tumor cells. Removing PD-L1 from dendritic-cell extracellular vesicles strengthened antitumor responses, CD8⁺ T-cell infiltration, and protection in melanoma models, while delivering PD-L1 siRNA in STAR vaccines suppressed dendritic-cell PD-L1, enhanced CD8⁺ T-cell activation, and produced durable prophylactic and therapeutic immunity in melanoma and colorectal cancer models 42377985Jun 42503762Jul. This shifts the design principle for cell- and vesicle-based vaccines from adding stimulatory signals alone to actively eliminating PD-L1 from the therapeutic antigen-presenting material.
Papers
The 76 papers from the last 6 months that study CD274 molecule directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Breast Cancer Immune Evasion (16)
- Strategy for modular assembly of tetravalent, multispecific antibodies. Protein science : a publication of the Protein Society · 18 Sept 2026 PMID 42757708
- The AR/ARD1/DLGAP5 Axis Drives Oncogenesis and Immune Evasion via PD-L1 Upregulation in Androgen Receptor-Positive Triple-Negative Breast Cancer. Translational research : the journal of laboratory and clinical medicine · 16 Sept 2026 PMID 42749183
- Identification of a circulating miR-6838-5p/miR-195-5p signature in invasive ductal breast carcinoma. Molecular biology reports · 16 Sept 2026 PMID 42747628
- HighMorph: De Novo Cyclic Peptide Sequence Design via Protein-Protein Interaction Recapitulation. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720486
- AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins. Nature communications · 20 Aug 2026 PMID 42624861
- A Single-Amino-Acid Ligand for LAT1: A Minimalist and Modular Platform for Lysosome-Targeted Degradation of Membrane Proteins. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 3 Aug 2026 PMID 42545113
- Personalized Autologous Vaccines Activate Stimulator of Interferon Gene and Suppress Dendritic Cell Programmed Death Ligand 1 to Potentiate Antitumor Immunity. ACS nano · 27 Jul 2026 PMID 42503762
- Eliminating PD-L1 on Dendritic Cell Extracellular Vesicles for Immunotherapy Potentiates Immune-Mediated Tumour Rejection in Mice. Journal of extracellular vesicles · 30 Jun 2026 PMID 42377985
- Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell · 22 Jun 2026 PMID 42330950
- Discovery of Novel Dual Small-Molecule Inhibitors Targeting SHP2 and NAMPT for Overcoming Resistance to Allosteric SHP2 Inhibition. Journal of medicinal chemistry · 22 Jun 2026 PMID 42324937
- Co-Delivery of Chemo and Immune Drugs by Prussian Blue Nanocubes for Combinational Therapy and T1-T2W MR Imaging of MDA-MB-231. ACS applied bio materials · 16 Jun 2026 PMID 42299821
- Neutrophil regulation of immunotherapy for cancer is controlled by type II interferon. Immunity · 15 Jun 2026 PMID 42296966
- An Aptamer-Engineered Phenotyping System for Extracellular Vesicles Based on Honeycomb-like Melamine-Formaldehyde Microspheres and Carbon Dot Nanozymes. Analytical chemistry · 15 Jun 2026 PMID 42296185
- Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 26 May 2026 PMID 42189888
- ALG1-mediated PDL1 glycosylation drives macrophage m2 polarization to promote bladder cancer progression. Cell death and differentiation · 21 May 2026 PMID 42168360
- Lactobacillus rhamnosus modulates gut microbiota and tyrosine metabolism to potentiate PD-1-mediated anti-tumor immunity in triple-negative breast cancer. International immunopharmacology · 20 May 2026 PMID 42161051
Tumor Immune Evasion (13)
- Engineered probiotics for tumor-targeted combination chemoimmunotherapy. Science translational medicine · 16 Sept 2026 PMID 42748218
- Integrin α2 (CD49b) blockade remodels the tumor immune microenvironment and enhances anti-PD-L1 therapy in 4T1 breast cancer model. Breast cancer research and treatment · 16 Sept 2026 PMID 42747603
- CD73 and PD-L1 expression in WHO grade 1 and grade 2 meningiomas: an exploratory analysis of purinergic and immune-related profiles. Journal of neuro-oncology · 15 Sept 2026 PMID 42736467
- Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy. Science advances · 11 Sept 2026 PMID 42726873
- Synchronizing immunity and angiogenesis in lung adenocarcinoma: bridging biological synergy and clinical translation. Cancer biology & therapy · 8 Sept 2026 PMID 42708433
- Targeting CTGF+ cancer-associated fibroblasts disrupts tumor-stroma crosstalk in pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America · 2 Sept 2026 PMID 42685072
- Single in situ intratumoral low‑dose shikonin hydrogel plus mild photothermal therapy elicits systemic antitumor immunity in immune‑cold triple‑negative breast cancer. International journal of oncology · 21 Aug 2026 PMID 42627061
- Compound kushen injection inhibits immune evasion of hepatocellular carcinoma cells via reducing O-GlcNAcylation of Pd-L1. Autoimmunity · 24 Jul 2026 PMID 42495854
- In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models. Cancer immunology research · 8 Jul 2026 PMID 42418729
- Biochemical Structure Evolved Pyridine-Activated Carbon Dots Co-Assembly as Precision Antitumor Nanozyme. Angewandte Chemie (International ed. in English) · 11 Jun 2026 PMID 42272358
- TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy. Cancer research · 10 Jun 2026 PMID 42268285
- Sulconazole Suppresses Colorectal Cancer Immune Evasion by Inhibiting Glycolysis to Upregulate OVOL2 PARylation and Induce PANoptosis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 8 Jun 2026 PMID 42252920
- Exosomal circFXR1 drives immune evasion and tumor progression through dual regulation of PD-L1 and mTOR signaling in gastric cancer. Cancer letters · 30 May 2026 PMID 42217559
PD-1/PD-L1 Immunotherapy (11)
- Discovery and Crystallographic Study of Water-Soluble Quaternary Ammonium-Based PD-1/PD-L1 Inhibitors with Anti-Angiogenic Activity. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720488
- PRKX-mediated stabilization of PD-L1 characterizes an immunosuppressive gastric cancer subtype. Journal for immunotherapy of cancer · 9 Sept 2026 PMID 42716706
- Conserved miRNA regulators of PD-1/PD-L1 in glioblastoma and colorectal cancer. RNA biology · 19 Aug 2026 PMID 42616478
- Viral coinfections and checkpoint-marker expression in HIV: An exploratory HCV-Related CD4⁺ T-Cell PD-L1 pattern. Immunologic research · 11 Aug 2026 PMID 42579169
- Checkpoint-insulated triple-signal artificial antigen-presenting cells drive antigen relay and systemic antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America · 5 Aug 2026 PMID 42555643
- Survival Impact of Programmed Cell Death Ligand-1 Expression in Patients With Epithelial Ovarian Carcinoma. Cancer reports (Hoboken, N.J.) · 30 Jul 2026 PMID 42530487
- Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data. Journal of hematology & oncology · 21 Jul 2026 PMID 42477829
- Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event. Immunologic research · 1 Jul 2026 PMID 42384108
- Glucose and Lactate Cooperatively Deprived by a PD-1-Presenting Nanoemulsion for Potentiated Antitumor Immunotherapy. ACS nano · 10 Jun 2026 PMID 42266067
- Toward Nano-Nutritional Medicine: A Remotely Activated Trans-Vaccenic Acid-Based Lipid Nanoparticles for Enhancing Immune Checkpoint Blockade Therapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Jun 2026 PMID 42261893
- A Comparative Study of Mesenchymal Stem Cell Derived From Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Through a Trophoblast-like Stage and Bone Marrow-derived Mesenchymal Stem Cells in Treating Acute Xenogeneic Graft-versus-host Disease in Humanized Mice. Transplantation · 9 Jun 2026 PMID 42260632
PD-L1 Targeting Strategies (11)
- PD-L1 Expression in Uterine Mesenchymal Tumors: A Comparative Immunohistochemical Analysis. The journal of obstetrics and gynaecology research · 23 Sept 2026 PMID 42773568
- Injectable phage-loaded silk microparticles achieve efficient tumor immunotherapy. Journal of materials chemistry. B · 7 Sept 2026 PMID 42703960
- Targeting PD-L1 Glycosylation with Site-Specific Aptamers for Enhanced Immune Checkpoint Blockade. Nano letters · 19 Aug 2026 PMID 42616376
- Discovery of natural product-derived rosavin as a programmed death-ligand 1 inhibitor for cancer immunotherapy. Phytomedicine : international journal of phytotherapy and phytopharmacology · 24 Jul 2026 PMID 42497523
- Splicing-mediated control of hnRNPD isoform switching by SRSF2 drives PD-L1-dependent immune evasion in gallbladder cancer. Oncogene · 20 Jul 2026 PMID 42477458
- Checkpoint inhibitors create rogue regulatory T cells. The Journal of clinical investigation · 1 Jul 2026 PMID 42383349
- Integrating PD-L1-targeted radioligand with protein degradation for precision tumor theranostics. Journal of controlled release : official journal of the Controlled Release Society · 29 Jun 2026 PMID 42372826
- Programmed cell death protein 1 (PD-1) / programmed cell death ligand 1 (PD-L1) in multiple myeloma. Journal of the Egyptian National Cancer Institute · 17 Jun 2026 PMID 42307688
- Multifunctional copper complex-mediated self-blocking plasmid delivery of PD-L1 for tumor chemoimmunotherapy. Colloids and surfaces. B, Biointerfaces · 3 Jun 2026 PMID 42235197
- New thiazole-biaryls as small molecule immunomodulators (SMIs) targeting PD-1/PD-L1 axis. Bioorganic & medicinal chemistry letters · 20 May 2026 PMID 42162747
- PRXL2B facilitates the progression of hepatocellular carcinoma and the therapeutic efficacy of oncolytic adenovirus H101 through the PI3K/AKT/PD-L1 axis. Bioscience trends · 20 May 2026 PMID 42161529
Squamous Cancer Immunotherapy (9)
- Salvage Chemotherapy After Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957236
- Exploring spatial heterogeneity of PD-L1 and c-MET expression in oral squamous cell carcinoma. Oral and maxillofacial surgery · 16 Sept 2026 PMID 42747499
- GMPS promotes cervical squamous cell carcinoma cell immune evasion through USP7-mediated deubiquitination of PDL1. Human cell · 7 Sept 2026 PMID 42704520
- Cytokines and chemokines in plasma as markers reflecting immunophenotype of head and neck squamous cell carcinoma. Human cell · 2 Sept 2026 PMID 42684559
- Programmed Death-Ligand 1 (PD-L1) expression and clinical outcomes in oral squamous cell carcinoma: evidence from a large clinical cohort. Oral and maxillofacial surgery · 28 Aug 2026 PMID 42665707
- Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade. Journal for immunotherapy of cancer · 26 Aug 2026 PMID 42648751
- A hypoxia-responsive migrasome-related lncRNA signature predicts prognosis and suggests the MSC-AS1/ITGA5 axis as a potential therapeutic target in head and neck squamous cell carcinoma. Functional & integrative genomics · 1 Jul 2026 PMID 42380675
- Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research · 25 Jun 2026 PMID 42347893
- CDK4/6 inhibition uncovers subtype-specific vulnerabilities and immune-related responses in esophageal squamous cell carcinoma. Cell death & disease · 29 May 2026 PMID 42215475
Colorectal Cancer Immunotherapy Resistance (8)
- Targeting the NAT1-ENO1-Lactate Axis Destabilizes PD-L1 to Reinvigorate Antitumor Immunity in Colorectal Cancer. MedComm · 23 Jul 2026 PMID 42491336
- Osteopontin mediates acquired resistance to hypoxia-inducing antiangiogenics and promotes anti-PD-L1 refractoriness in breast cancer models. The Journal of clinical investigation · 15 Jul 2026 PMID 42454487
- A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377085
- Preclinical evaluation of [68Ga]Ga-MRCP: a potential radiotracer for imaging PD-L1 expression in colorectal cancer. Bioorganic chemistry · 27 Jun 2026 PMID 42364379
- Gemcitabine enhanced the sensitivity of colorectal cancer to anti-PD-L1 therapy by promoting lactylation. International immunopharmacology · 20 Jun 2026 PMID 42322856
- Tumor-Specific Delivery of CD28 siRNA via Lyso-PC C-16 Modified Lipid Nanoparticles Overcomes Anti-PD-1 Resistance by Remodeling Tumor Microenvironment. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Jun 2026 PMID 42261788
- Chemically Masked aPD-L1-Sialidase Conjugate for Tumor-Specific Desialylation and Immunotherapy. Angewandte Chemie (International ed. in English) · 4 Jun 2026 PMID 42241306
- Combating small extracellular vesicle-mediated immunological barriers in the tumor microenvironment via strategically activatable PEGylated peptides. Signal transduction and targeted therapy · 27 May 2026 PMID 42204141
PD-L1 Therapy in Lung Cancer (8)
- Targeting the PD-L1-induced PDK4/GLS metabolic axis overcomes anti-PD-1 resistance in non-small cell lung cancer. Journal for immunotherapy of cancer · 2 Sept 2026 PMID 42686373
- Radiosensitization effect of PD-L1-targeted small molecules with direct antitumor activity on non-small cell lung Cancer. Bioorganic chemistry · 14 Jul 2026 PMID 42447749
- Deep learning of CT imaging predicts PD-L1 expression and immunotherapy response in metastatic NSCLC: A multi-center study. Cancer letters · 18 Jun 2026 PMID 42314966
- [Translated article] Real world outcomes of first-line pembrolizumab in metastatic non-small-cell lung cancer. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 12 Jun 2026 PMID 42285782
- Neoadjuvant nivolumab plus chemotherapy in resectable NSCLC: A pharmacological outcome study. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262212
- Targeting XIAP-coordinated PKC signaling resensitizes PD-1-refractory tumors for rechallenge. Proceedings of the National Academy of Sciences of the United States of America · 3 Jun 2026 PMID 42234523
- Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA · 1 Jun 2026 PMID 42224490
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial. Lancet (London, England) · 29 May 2026 PMID 42214392
By study type
Clinical trials (6)
- Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade. Journal for immunotherapy of cancer · 26 Aug 2026 PMID 42648751
- A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377085
- Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research · 25 Jun 2026 PMID 42347893
- Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA · 1 Jun 2026 PMID 42224490
- Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial. Lancet (London, England) · 29 May 2026 PMID 42214392
- Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 26 May 2026 PMID 42189888
Observational studies and case reports (11)
- Salvage Chemotherapy After Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. In vivo (Athens, Greece) · 29 Oct 2026 PMID 42957236
- PD-L1 Expression in Uterine Mesenchymal Tumors: A Comparative Immunohistochemical Analysis. The journal of obstetrics and gynaecology research · 23 Sept 2026 PMID 42773568
- Identification of a circulating miR-6838-5p/miR-195-5p signature in invasive ductal breast carcinoma. Molecular biology reports · 16 Sept 2026 PMID 42747628
- Exploring spatial heterogeneity of PD-L1 and c-MET expression in oral squamous cell carcinoma. Oral and maxillofacial surgery · 16 Sept 2026 PMID 42747499
- CD73 and PD-L1 expression in WHO grade 1 and grade 2 meningiomas: an exploratory analysis of purinergic and immune-related profiles. Journal of neuro-oncology · 15 Sept 2026 PMID 42736467
- Programmed Death-Ligand 1 (PD-L1) expression and clinical outcomes in oral squamous cell carcinoma: evidence from a large clinical cohort. Oral and maxillofacial surgery · 28 Aug 2026 PMID 42665707
- Survival Impact of Programmed Cell Death Ligand-1 Expression in Patients With Epithelial Ovarian Carcinoma. Cancer reports (Hoboken, N.J.) · 30 Jul 2026 PMID 42530487
- Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event. Immunologic research · 1 Jul 2026 PMID 42384108
- Deep learning of CT imaging predicts PD-L1 expression and immunotherapy response in metastatic NSCLC: A multi-center study. Cancer letters · 18 Jun 2026 PMID 42314966
- Programmed cell death protein 1 (PD-1) / programmed cell death ligand 1 (PD-L1) in multiple myeloma. Journal of the Egyptian National Cancer Institute · 17 Jun 2026 PMID 42307688
- Neoadjuvant nivolumab plus chemotherapy in resectable NSCLC: A pharmacological outcome study. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262212
Human data, design not indexed (8)
- Strategy for modular assembly of tetravalent, multispecific antibodies. Protein science : a publication of the Protein Society · 18 Sept 2026 PMID 42757708
- HighMorph: De Novo Cyclic Peptide Sequence Design via Protein-Protein Interaction Recapitulation. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720486
- Cytokines and chemokines in plasma as markers reflecting immunophenotype of head and neck squamous cell carcinoma. Human cell · 2 Sept 2026 PMID 42684559
- Conserved miRNA regulators of PD-1/PD-L1 in glioblastoma and colorectal cancer. RNA biology · 19 Aug 2026 PMID 42616478
- Viral coinfections and checkpoint-marker expression in HIV: An exploratory HCV-Related CD4⁺ T-Cell PD-L1 pattern. Immunologic research · 11 Aug 2026 PMID 42579169
- Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data. Journal of hematology & oncology · 21 Jul 2026 PMID 42477829
- An Aptamer-Engineered Phenotyping System for Extracellular Vesicles Based on Honeycomb-like Melamine-Formaldehyde Microspheres and Carbon Dot Nanozymes. Analytical chemistry · 15 Jun 2026 PMID 42296185
- New thiazole-biaryls as small molecule immunomodulators (SMIs) targeting PD-1/PD-L1 axis. Bioorganic & medicinal chemistry letters · 20 May 2026 PMID 42162747
Preclinical: animal, cell and lab studies (40)
- Engineered probiotics for tumor-targeted combination chemoimmunotherapy. Science translational medicine · 16 Sept 2026 PMID 42748218
- Integrin α2 (CD49b) blockade remodels the tumor immune microenvironment and enhances anti-PD-L1 therapy in 4T1 breast cancer model. Breast cancer research and treatment · 16 Sept 2026 PMID 42747603
- Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy. Science advances · 11 Sept 2026 PMID 42726873
- Discovery and Crystallographic Study of Water-Soluble Quaternary Ammonium-Based PD-1/PD-L1 Inhibitors with Anti-Angiogenic Activity. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720488
- PRKX-mediated stabilization of PD-L1 characterizes an immunosuppressive gastric cancer subtype. Journal for immunotherapy of cancer · 9 Sept 2026 PMID 42716706
- Synchronizing immunity and angiogenesis in lung adenocarcinoma: bridging biological synergy and clinical translation. Cancer biology & therapy · 8 Sept 2026 PMID 42708433
- GMPS promotes cervical squamous cell carcinoma cell immune evasion through USP7-mediated deubiquitination of PDL1. Human cell · 7 Sept 2026 PMID 42704520
- Injectable phage-loaded silk microparticles achieve efficient tumor immunotherapy. Journal of materials chemistry. B · 7 Sept 2026 PMID 42703960
- Targeting the PD-L1-induced PDK4/GLS metabolic axis overcomes anti-PD-1 resistance in non-small cell lung cancer. Journal for immunotherapy of cancer · 2 Sept 2026 PMID 42686373
- Targeting CTGF+ cancer-associated fibroblasts disrupts tumor-stroma crosstalk in pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America · 2 Sept 2026 PMID 42685072
- Single in situ intratumoral low‑dose shikonin hydrogel plus mild photothermal therapy elicits systemic antitumor immunity in immune‑cold triple‑negative breast cancer. International journal of oncology · 21 Aug 2026 PMID 42627061
- AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins. Nature communications · 20 Aug 2026 PMID 42624861
- Targeting PD-L1 Glycosylation with Site-Specific Aptamers for Enhanced Immune Checkpoint Blockade. Nano letters · 19 Aug 2026 PMID 42616376
- Checkpoint-insulated triple-signal artificial antigen-presenting cells drive antigen relay and systemic antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America · 5 Aug 2026 PMID 42555643
- Personalized Autologous Vaccines Activate Stimulator of Interferon Gene and Suppress Dendritic Cell Programmed Death Ligand 1 to Potentiate Antitumor Immunity. ACS nano · 27 Jul 2026 PMID 42503762
- Discovery of natural product-derived rosavin as a programmed death-ligand 1 inhibitor for cancer immunotherapy. Phytomedicine : international journal of phytotherapy and phytopharmacology · 24 Jul 2026 PMID 42497523
- Compound kushen injection inhibits immune evasion of hepatocellular carcinoma cells via reducing O-GlcNAcylation of Pd-L1. Autoimmunity · 24 Jul 2026 PMID 42495854
- Osteopontin mediates acquired resistance to hypoxia-inducing antiangiogenics and promotes anti-PD-L1 refractoriness in breast cancer models. The Journal of clinical investigation · 15 Jul 2026 PMID 42454487
- Radiosensitization effect of PD-L1-targeted small molecules with direct antitumor activity on non-small cell lung Cancer. Bioorganic chemistry · 14 Jul 2026 PMID 42447749
- In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models. Cancer immunology research · 8 Jul 2026 PMID 42418729
- Checkpoint inhibitors create rogue regulatory T cells. The Journal of clinical investigation · 1 Jul 2026 PMID 42383349
- A hypoxia-responsive migrasome-related lncRNA signature predicts prognosis and suggests the MSC-AS1/ITGA5 axis as a potential therapeutic target in head and neck squamous cell carcinoma. Functional & integrative genomics · 1 Jul 2026 PMID 42380675
- Eliminating PD-L1 on Dendritic Cell Extracellular Vesicles for Immunotherapy Potentiates Immune-Mediated Tumour Rejection in Mice. Journal of extracellular vesicles · 30 Jun 2026 PMID 42377985
- Preclinical evaluation of [68Ga]Ga-MRCP: a potential radiotracer for imaging PD-L1 expression in colorectal cancer. Bioorganic chemistry · 27 Jun 2026 PMID 42364379
- Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell · 22 Jun 2026 PMID 42330950
- Discovery of Novel Dual Small-Molecule Inhibitors Targeting SHP2 and NAMPT for Overcoming Resistance to Allosteric SHP2 Inhibition. Journal of medicinal chemistry · 22 Jun 2026 PMID 42324937
- Gemcitabine enhanced the sensitivity of colorectal cancer to anti-PD-L1 therapy by promoting lactylation. International immunopharmacology · 20 Jun 2026 PMID 42322856
- Co-Delivery of Chemo and Immune Drugs by Prussian Blue Nanocubes for Combinational Therapy and T1-T2W MR Imaging of MDA-MB-231. ACS applied bio materials · 16 Jun 2026 PMID 42299821
- Neutrophil regulation of immunotherapy for cancer is controlled by type II interferon. Immunity · 15 Jun 2026 PMID 42296966
- Biochemical Structure Evolved Pyridine-Activated Carbon Dots Co-Assembly as Precision Antitumor Nanozyme. Angewandte Chemie (International ed. in English) · 11 Jun 2026 PMID 42272358
- TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy. Cancer research · 10 Jun 2026 PMID 42268285
- Glucose and Lactate Cooperatively Deprived by a PD-1-Presenting Nanoemulsion for Potentiated Antitumor Immunotherapy. ACS nano · 10 Jun 2026 PMID 42266067
- A Comparative Study of Mesenchymal Stem Cell Derived From Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Through a Trophoblast-like Stage and Bone Marrow-derived Mesenchymal Stem Cells in Treating Acute Xenogeneic Graft-versus-host Disease in Humanized Mice. Transplantation · 9 Jun 2026 PMID 42260632
- Sulconazole Suppresses Colorectal Cancer Immune Evasion by Inhibiting Glycolysis to Upregulate OVOL2 PARylation and Induce PANoptosis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 8 Jun 2026 PMID 42252920
- Chemically Masked aPD-L1-Sialidase Conjugate for Tumor-Specific Desialylation and Immunotherapy. Angewandte Chemie (International ed. in English) · 4 Jun 2026 PMID 42241306
- Multifunctional copper complex-mediated self-blocking plasmid delivery of PD-L1 for tumor chemoimmunotherapy. Colloids and surfaces. B, Biointerfaces · 3 Jun 2026 PMID 42235197
- Targeting XIAP-coordinated PKC signaling resensitizes PD-1-refractory tumors for rechallenge. Proceedings of the National Academy of Sciences of the United States of America · 3 Jun 2026 PMID 42234523
- Exosomal circFXR1 drives immune evasion and tumor progression through dual regulation of PD-L1 and mTOR signaling in gastric cancer. Cancer letters · 30 May 2026 PMID 42217559
- Combating small extracellular vesicle-mediated immunological barriers in the tumor microenvironment via strategically activatable PEGylated peptides. Signal transduction and targeted therapy · 27 May 2026 PMID 42204141
- Lactobacillus rhamnosus modulates gut microbiota and tyrosine metabolism to potentiate PD-1-mediated anti-tumor immunity in triple-negative breast cancer. International immunopharmacology · 20 May 2026 PMID 42161051
Unclassified: not yet indexed with MeSH (11)
- The AR/ARD1/DLGAP5 Axis Drives Oncogenesis and Immune Evasion via PD-L1 Upregulation in Androgen Receptor-Positive Triple-Negative Breast Cancer. Translational research : the journal of laboratory and clinical medicine · 16 Sept 2026 PMID 42749183
- A Single-Amino-Acid Ligand for LAT1: A Minimalist and Modular Platform for Lysosome-Targeted Degradation of Membrane Proteins. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 3 Aug 2026 PMID 42545113
- Targeting the NAT1-ENO1-Lactate Axis Destabilizes PD-L1 to Reinvigorate Antitumor Immunity in Colorectal Cancer. MedComm · 23 Jul 2026 PMID 42491336
- Splicing-mediated control of hnRNPD isoform switching by SRSF2 drives PD-L1-dependent immune evasion in gallbladder cancer. Oncogene · 20 Jul 2026 PMID 42477458
- Integrating PD-L1-targeted radioligand with protein degradation for precision tumor theranostics. Journal of controlled release : official journal of the Controlled Release Society · 29 Jun 2026 PMID 42372826
- [Translated article] Real world outcomes of first-line pembrolizumab in metastatic non-small-cell lung cancer. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 12 Jun 2026 PMID 42285782
- Toward Nano-Nutritional Medicine: A Remotely Activated Trans-Vaccenic Acid-Based Lipid Nanoparticles for Enhancing Immune Checkpoint Blockade Therapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Jun 2026 PMID 42261893
- Tumor-Specific Delivery of CD28 siRNA via Lyso-PC C-16 Modified Lipid Nanoparticles Overcomes Anti-PD-1 Resistance by Remodeling Tumor Microenvironment. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Jun 2026 PMID 42261788
- CDK4/6 inhibition uncovers subtype-specific vulnerabilities and immune-related responses in esophageal squamous cell carcinoma. Cell death & disease · 29 May 2026 PMID 42215475
- ALG1-mediated PDL1 glycosylation drives macrophage m2 polarization to promote bladder cancer progression. Cell death and differentiation · 21 May 2026 PMID 42168360
- PRXL2B facilitates the progression of hepatocellular carcinoma and the therapeutic efficacy of oncolytic adenovirus H101 through the PI3K/AKT/PD-L1 axis. Bioscience trends · 20 May 2026 PMID 42161529
Written from 76 PubMed abstracts, each one listed by PMID above. Published: 2026-07-02. Last written: 2026-08-26 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.